BMY.NYSEBristol Myers Squibb CO
DEF 14A: Bristol Myers Squibb Outlines Strategy and Governance in 2024 Proxy Statement
Sentiment:
Proxy Statement
Bristol Myers Squibb's 2024 proxy statement details the company's strategic priorities, governance practices, and executive compensation.
Summary
- Bristol Myers Squibb's 2024 proxy statement outlines key aspects of the company's operations and governance.
- The company's annual revenues reached $45.0 billion, driven by a diversified portfolio and innovative growth products.
- New Product Portfolio revenues increased by 77% year-over-year.
- Bristol Myers Squibb invested $9.3 billion in R&D.
- The company announced a 5.6% quarterly dividend increase, marking the 14th consecutive year of such increases.
- The Board of Directors has nominated 10 current directors for election at the upcoming Annual Meeting.
- Christopher Boerner assumed the CEO role on November 1, 2023, and will become Board Chair on April 1, 2024.
- The company is focused on expanding its pipeline and delivering 16 new products by 2030.
- Bristol Myers Squibb aims to deliver approximately 10 investigational new drugs per year.
- The company is committed to environmental, social, and governance (ESG) initiatives, including reducing its environmental impact and advancing equitable access to medicines.
- In 2023, Bristol Myers Squibb donated over $4 billion worth of medicines to assist over 171,000 patients in the U.S.
- The company is working to address health inequities and expand access to medicines in lowand middle-income countries.
- Bristol Myers Squibb is committed to increasing diversity in clinical trials and has located 58% of its U.S. clinical trial sites in diverse metro areas.
- The company is focused on fostering a high-performing and inclusive global workforce.
- The Board recommends shareholders vote for the election of directors, the advisory vote on executive compensation, the ratification of the independent auditor, and against the shareholder proposals.
Sentiment
Score: 7
Explanation: The document presents a balanced view, highlighting both achievements and challenges. The tone is optimistic about future growth but acknowledges current headwinds.
Positives
- The company has a diversified portfolio and innovative growth products.
- Bristol Myers Squibb is committed to ESG initiatives and health equity.
- The company has a strong financial foundation and is returning capital to shareholders.
- The company is focused on expanding its pipeline and delivering new products.
- The company has a high-performing and inclusive global workforce.
- The company has a history of scientific excellence and transforming patient outcomes.
- The company is committed to responsible drug pricing and transparency.
- The company has a robust governance model and is committed to ethical business conduct.
Negatives
- Total Revenues decreased 2% compared to 2022.
- Non-GAAP diluted EPS decreased 2% compared to 2022.
- Recent LOE Products decreased 34% both as reported and excluding foreign exchange.
- The company faces upcoming losses of exclusivity and other challenges.
- The company is facing increased competition and a dynamic regulatory and macro-economic environment.
Risks
- Potential legislative or regulatory actions impacting the pharmaceutical industry, including drug pricing and access.
- Intellectual property protection and upcoming losses of exclusivity.
- Competition in the biopharmaceutical industry.
- Business continuity risks.
- Key environmental, social, and governance risks, including human capital management and inclusion and diversity goals.
- Cybersecurity risks.
Future Outlook
The company is focused on long-term sustainable growth and aims to become one of the fastest-growing innovators in its space by the end of the decade.
Management Comments
- Christopher Boerner: 'We know our path to long-term sustainable growth is not linear. But it is clearly mapped.'
- Christopher Boerner: 'With a relentless focus on improving our growth profile, we have the potential to transform into one of the fastest-growing innovators in our space and emerge in the last part of the decade well positioned to deliver sustainable, top-tier growth.'
Industry Context
The announcement reflects the ongoing trends in the biopharmaceutical industry, including a focus on R&D, portfolio diversification, and strategic acquisitions to drive growth and address upcoming losses of exclusivity.
Comparison to Industry Standards
- The document mentions several competitors, including AbbVie Inc., Amgen Inc., Biogen Inc., Eli Lilly and Company, Gilead Sciences Inc., Johnson & Johnson, Merck & Co., Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Roche Holding AG, Novartis AG, and Sanofi.
- The document mentions that Dr. Boerners total compensation package is positioned at approximately the 25th percentile among Chief Executive Officers within our current primary peer group and PHRA survey peers.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Giovanni Caforio | Christopher Boerner | 2023-11-01 | Retirement of Giovanni Caforio |
| Executive Chair of the Board | Giovanni Caforio | Christopher Boerner | 2024-04-01 | Retirement of Giovanni Caforio |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Officer Exculpation | Proposed amendment to the Certificate of Incorporation to provide for limited officer exculpation. | Upon shareholder approval | Aims to attract and retain top talent by providing officers with similar liability protection as directors. |
Related Party Transactions
- Certain retirement plans use BlackRock and its affiliates to provide investment management services, with fees paid to BlackRock totaling approximately $1.56 million in 2023.
- Vanguard acts as an investment manager with respect to certain investment options under savings and thrift plans, receiving approximately $650,000 in fees during 2023.
Stakeholder Impact
- Shareholders: The document outlines the company's strategy to drive long-term value and return capital.
- Employees: The company is committed to fostering an inclusive and diverse workforce and providing competitive compensation and benefits.
- Patients: The company is focused on discovering, developing, and delivering innovative medicines to help patients prevail over serious diseases.
- Communities: The company is committed to ESG initiatives and addressing health inequities.
Next Steps
- Shareholders will vote on the proposed items at the Annual Meeting on May 7, 2024.
- The company will continue to execute its strategy to renew its product pipeline and drive long-term value.
- The company will continue to monitor and adapt to changes in the regulatory environment.
- The company will continue to engage with shareholders and stakeholders on key issues.
Key Dates
| Date | Description |
|---|---|
| 1887 | Year Bristol Myers Squibb was founded. |
| 2002 | Sarbanes-Oxley Act enacted, requiring procedures for handling complaints regarding accounting matters. |
| 2009-12 | BMS discontinued service accruals under the Retirement Plan and the BEPRetirement Plan in the U.S for active plan participants and closed the plan to new entrants. |
| 2010-12 | Bristol Myers Squibb joined the U.N. Global Compact. |
| 2015 | Christopher Boerner joined Bristol Myers Squibb. |
| 2016 | Bristol Myers Squibb adopted proxy access. |
| 2019-02-01 | The qualified Pension Plan was terminated. |
| 2020-08 | Bristol Myers Squibb and the Bristol Myers Squibb Foundation announced a $300 million investment over five years to address health equity commitments. |
| 2022-01 | Mr. Arduini was appointed President and Chief Executive Officer of GE Healthcare. |
| 2022 | The company published its 2022 COP. |
| 2022 | The company received a shareholder proposal for the 2023 Annual Meeting from a group of shareholders asking the Board to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for additional patent protection on new innovations after the main active ingredient/molecule patent(s) have been filed. |
| 2022 | BMS achieved near gender parity at the executive levels as of December 2022. |
| 2022 | The Inflation Reduction Act of 2022 was enacted. |
| 2022-12 | The Committee determined to make no changes to the director compensation program for service as a director in 2023. |
| 2023-03-10 | Effective date of long-term incentive awards. |
| 2023-04-01 | Christopher Boerner will also serve as Chair of the Board in addition to Chief Executive Officer. |
| 2023-04-26 | Announcement of CEO succession plan. |
| 2023-05-02 | Dr. Boerner was appointed as a member of the Board. |
| 2023-10 | Bristol Myers Squibb entered into a definitive merger agreement to acquire Mirati Therapeutics. |
| 2023-10-25 | Announcement that Dr. Caforio would not stand for re-election to the Board at the 2024 Annual Meeting of Shareholders, and would retire from the Board, effective April 1, 2024. |
| 2023-11-01 | Christopher Boerner assumed the role of CEO. |
| 2023-12 | Bristol Myers Squibb entered into a definitive merger agreement to acquire RayzeBio. |
| 2023-12 | Bristol Myers Squibb entered into a definitive merger agreement to acquire Karuna Therapeutics. |
| 2023-12 | The Committee approved a separate policy for the Recoupment of Compensation for Accounting Restatements, pursuant to and consistent with, Rule 303A.14 of the New York Stock Exchange which applies to current and certain former executive officers and requires the Board to recoup excess compensation paid to covered executive officers as a result of a financial statement restatement, regardless of any misconduct, fault or illegal activity on the part of the covered executive officer. |
| 2024-01 | Transactions closed in first quarter of 2024. |
| 2024-03-14 | Record date for the Annual Meeting of Shareholders. |
| 2024-03-28 | Date of the proxy statement. |
| 2024-04-01 | Giovanni Caforio will retire from the Board and Christopher Boerner will become Board Chair. |
| 2024-04 | The company published its fourth Environmental, Social & Governance (ESG) Report, which incorporates its inclusion and diversity efforts. |
| 2024-05-07 | Date of the Annual Meeting of Shareholders. |
| 2024-09-26 | PDUFA date for KarXT. |
| 2024-10-29 | Earliest date for receipt of notice for proxy access for the 2025 Annual Meeting. |
| 2024-11-28 | Latest date for receipt of notice for proxy access for the 2025 Annual Meeting. |
| 2024-11-28 | Deadline for receipt of shareholder proposals for the 2025 Annual Meeting. |
| 2025-01-07 | Earliest date for receipt of notice for proposed action at the 2025 Annual Meeting. |
| 2025-02-06 | Latest date for receipt of notice for proposed action at the 2025 Annual Meeting. |
| 2025-03-08 | Deadline for notice of intent to solicit proxies in support of director nominees for the 2025 Annual Meeting. |
| 2030 | Goal to deliver 16 new products by 2030. |
Keywords
Executive compensation, Corporate governance, Pharmaceuticals, Biopharmaceuticals, R&D, ESG, Clinical trials, Board of Directors, Shareholder proposals, Financial performance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.